Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data.
about
CDK6 as a key regulator of hematopoietic and leukemic stem cell activationCharacterization of chronic myeloid leukemia stem cells.Targeted therapy in Ewing sarcoma.Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.Chronic myeloid leukemia: the basis of treatment for tomorrow.
P2860
Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Optimising chronic myeloid leu ...... clinical and laboratory data.
@ast
Optimising chronic myeloid leu ...... clinical and laboratory data.
@en
Optimising chronic myeloid leu ...... clinical and laboratory data.
@nl
type
label
Optimising chronic myeloid leu ...... clinical and laboratory data.
@ast
Optimising chronic myeloid leu ...... clinical and laboratory data.
@en
Optimising chronic myeloid leu ...... clinical and laboratory data.
@nl
prefLabel
Optimising chronic myeloid leu ...... clinical and laboratory data.
@ast
Optimising chronic myeloid leu ...... clinical and laboratory data.
@en
Optimising chronic myeloid leu ...... clinical and laboratory data.
@nl
P1433
P1476
Optimising chronic myeloid leu ...... clinical and laboratory data.
@en
P2093
David A Irvine
Nicholas B Heaney
P356
10.1016/J.BLRE.2009.11.002
P577
2010-01-01T00:00:00Z